News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
Ardelyx to Receive a $5 Million Milestone Payment Company Narrows Timeline for its PHREEDOM trial and announces AMPLIFY, a new Phase 3 Trial evaluating tenapanor in combination with binders FREMONT, Calif. , Feb. 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) ( Ardelyx ) today announced that
View HTML
Toggle Summary Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C
FREMONT, Calif. , Nov. 13, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that  the U.S. Food and Drug Administration ( FDA ) has accepted for review the New Drug Application (NDA) for tenapanor for the treatment of patients with irritable bowel syndrome with constipation
View HTML
Toggle Summary Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019 FREMONT, Calif. , Nov. 7, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today reported business highlights and financial results for the third quarter ended September 30, 2018 .
View HTML
Toggle Summary Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Company Plans to Commence a Phase 2/3 Clinical Study Evaluating Tenapanor in Combination with Phosphate Binders FREMONT, Calif. , Oct. 26, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced the presentation of preclinical data suggesting therapeutic synergy of tenapanor in
View HTML
Toggle Summary Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
FREMONT, Calif. , Oct. 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this weekend at the American College of Gastroenterology
View HTML
Toggle Summary Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
FREMONT, Calif. , Oct. 4, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an investor event called "Renal Day" on Thursday, Oct. 11, 2018 , from 8 to 10 a.m. ET in New York City . This year's event is the first of an anticipated annual series of events, and will
View HTML
Toggle Summary Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
FREMONT, Calif. , Sept. 13, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) requesting U.S. marketing authorization of tenapanor for the treatment of patients with irritable bowel
View HTML
Toggle Summary Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
FREMONT, Calif. , Aug. 29, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that the novel mechanism of action for tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, has been published in the peer-reviewed journal Science Translational Medicine .
View HTML
Toggle Summary Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
Operating Runway Extended to Mid-2020 Preparing to Submit NDA for Tenapanor in IBS-C in Early Q4 2018 Conference Call to be Held Today at 4:30 p.m. ET FREMONT, Calif. , Aug. 7, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today reported business highlights and financial results for the second
View HTML
Toggle Summary Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
FREMONT, Calif. , Aug. 1, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August 7, 2018 . Management will host a conference call and webcast that afternoon at 4:30 p.m.
View HTML